PredictSURE IBD is now available to order in the United States from KSL Diagnostics
Enabling Better
Treatment of IBD
Prognostic test for IBD patients
Stratifies adult patients by risk of frequently relapsing disease
Based on a whole blood gene expression signature
Early testing aids optimal treatment choice
Test Overview
RT-qPCR test on RNA extracted from whole blood samples
Utilises gene expression data to generate a risk category that correlates with a patient’s risk of experiencing a frequently relapsing disease course
Indicated for use in adult (16 years or older) female and male IBD patients with active disease
Not recommended for use in patients receiving immunosuppressive therapy
CE marked
Right Patient
- PredictSURE IBD stratifies patients based on their risk of experiencing early and frequent relapses
Right Treatment
- Low-risk patients may benefit from less aggressive treatment
- High-risk patients may benefit from early aggressive therapy
Right Time
- Optimum treatment pathway can be commenced early
helping to deliver
Rapid Results in a Simple Format
- PredictSURE IBD test results are processed by our clinical lab partners using a secure cloud-based portal
- Data from the PredictSURE IBD assay is uploaded to the PredictSURE IBD portal
- Our proprietary algorithm then stratifies patients into high-risk and low-risk subgroups, generating a unique report for each patient
Kate, a patient who has been living with Crohn’s Disease for several years
“Crohn’s has always been a disease that’s constantly trying to gain ground. In the years after my diagnosis, failing my way through drugs of varying strength, I lost ground that I might never have had to give up if the people in charge of my care had a tool that allowed them to see a clearer picture of what I needed to stay well”.
Paul Lyons – VP Platform Delivery
Eoin McKinney – CSO
Andy Sandham, Chairman
